Loading organizations...
Meracle Health develops digital health technologies that focus on improving medication delivery for chronic respiratory diseases. The company offers a medical device designed to optimize the efficiency of medication administered into the lungs, particularly for conditions like asthma and COPD. This technology tracks medication intake data, enhancing the effectiveness of therapy and transforming disease management.
The company was founded by Rachel Hong, an engineer and entrepreneur with a background in medical engineering. Hong established Meracle Health with the insight that technology could significantly improve patient outcomes by optimizing the delivery of therapeutic interventions. Her vision was to bridge technological innovation with empathetic design to create smart solutions for respiratory care.
Meracle Health's products serve patients grappling with chronic respiratory ailments, providing them with more reliable and efficient treatment experiences. The company's long-term vision centers on ensuring better breathing for patients, aiming to bring relief and assurance through consistently optimizing therapeutic delivery and medication tracking.
Meracle Health has raised $660K across 1 funding round.
Meracle Health has raised $660K in total across 1 funding round.
Meracle Health has raised $660K across 1 funding round. Most recently, it raised $660K Seed in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $660K Seed | — | R3I Capital | Announced |
Meracle Health has raised $660K in total across 1 funding round.
Meracle Health's investors include R3i Capital.
Meracle Health is a Singapore-headquartered digital health startup developing The Whizz, a smart spacer device and mobile app platform that enhances inhaler medication delivery for patients with chronic respiratory conditions like asthma and COPD.[1][2][3][6] It serves children, the elderly, and vulnerable patients—who represent about 60% of cases—by addressing poor inhalation technique and compliance, which affect up to 7 in 10 patients and lead to doubled hospitalization rates and tripled healthcare costs.[2][3][6] The product provides real-time feedback during inhalation (like a "speedometer"), tracks usage data via gamification and reminders, and shares objective insights with doctors to improve control, reduce exacerbations by 50%, boost adherence by 40%, and refine technique by 60%.[1][3][4]
Launched in 2022 after clinical trials at National University Hospital (Singapore) and partnerships in Europe and India, Meracle has manufacturing ready, regulatory preparations underway (e.g., CE mark, HSA), and distributor engagements with pharma firms.[2][3][4] Future growth includes AI-driven predictive models for attack risks using behavioral and environmental data, plus hardware enhancements via Infineon collaboration.[1]
Meracle Health emerged from the personal frustration of co-founder Melvin Loh, whose family experienced frequent asthma exacerbations and ER visits despite medication and check-ups, highlighting gaps in technique and compliance.[2] Founded in Singapore around 2020 (pre-2022 launch), the team combines over 50 years in medical device development; Loh led innovations at NUS, commercializing 11 products and listing three companies on the Singapore stock exchange.[2]
The idea crystallized into The Whizz—a hardware spacer paired with an app—sparked by this real-world need.[2][3] Pivotal early traction came from usability and clinical trials at National University Hospital, proving 100% improvement in technique/compliance, plus multi-center trials in Europe (Luxembourg, Germany, Belgium) and India.[3] By 2022, they partnered with SmartDev for Android app development (matching iOS), enabling launch and positive feedback on outcomes.[4]
Meracle rides the digital therapeutics and AI health wave, targeting a massive market where chronic respiratory diseases affect millions amid rising pollution and aging populations—yet 70% of asthma patients remain poorly controlled due to delivery flaws.[1][2][3][6] Timing aligns with post-pandemic telehealth boom and regulatory pushes for connected devices (e.g., CE, HSA), plus pharma demand for adherence data.[2][3]
Market tailwinds include AI personalization (e.g., pollen/pollution forecasts) and hardware-software integration, positioning Meracle against static inhalers.[1] It influences the ecosystem by setting benchmarks for real-time feedback and predictive care, partnering with distributors (Vicplas, Forefront) and trials across Asia/Europe, while enabling pharma access and cost savings—potentially via 2023 IPO plans (noted pre-2025).[2][3]
Meracle's edge in real-time, empathetic tech positions it for explosive growth in personalized respiratory care, with AI predictions and global expansion (e.g., localization via SmartDev) driving adoption.[1][4] Trends like AI-health integration, value-based care, and semiconductor advances (Infineon) will accelerate its trajectory, potentially capturing high-cost segments through pharma tie-ups and regulatory wins.[1][2][3]
Expect influence to grow via data ecosystems empowering patients/doctors, evolving from device-maker to AI platform leader—breathing better, as they say, to live better.[1]
